Amgen Inc.

AMGNNASDAQ

Market cap212.19B USDAs of Sep 22, 2026

Healthcare· Drug Manufacturers - General· US

$393.16

Session change unavailable

Market closed · NASDAQ

Status checked Oct 24, 2026, 9:36 PM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

Amgen Inc. (AMGN)

Loading market observation…

Research downloads are available with Pro.

Financial Metrics vs. Sector

Upgrade to Plus or Pro to explore this analysis.

Explore plans

Dated financials

As of Sep 22, 2026 · 48 of 48 observations available. Each value retains its reporting period. Trailing 12 months and fiscal-year earnings are separate measures. Financial observations and company disclosures retain their own dates. An observation date is not a filing publication date.

Price and valuation

Closing price was observed on Sep 21, 2026 (as of snapshot date Sep 22, 2026). Financial reporting periods are shown with each observation.

Closing price: 393.16 USD/shares; At Sep 21, 2026; Provider observation · observed Sep 22, 2026
Market capitalization: 212.19B USD; At Sep 21, 2026; Provider observation · observed Sep 22, 2026
P/E · trailing 12 months: 24.24x; Provider TTM · observed Sep 22, 2026
Free cash flow yield: 4.80%; Provider TTM · observed Sep 22, 2026

Compare within the sector

Price to book is particularly useful for financial companies. Price to sales can support comparisons when earnings are negative.

Price to sales: 5.57x; Provider TTM · observed Sep 22, 2026
Price to book: 18.16x; Provider TTM · observed Sep 22, 2026

Additional valuation measures

Fiscal-year P/E uses the last completed financial year. Earnings yield expresses earnings relative to price as a percentage.

P/E · fiscal year: 27.10x; At Sep 18, 2026
Earnings yield: 4.13%; Provider TTM · observed Sep 22, 2026

Financial statements and ratios

Company disclosures

Revenue · quarter: 10.05B USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Gross profit · quarter: 7.24B USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Operating income · quarter: 3.51B USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Net income · quarter: 2.38B USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Diluted EPS · quarter: 4.37 USD/shares; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Operating cash flow · quarter: 4B USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Capital expenditure · quarter: 513M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Free cash flow · quarter: 3.49B USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026

View dated valuation comparison

Research snapshot

Loading research…

Amgen Inc. research

Loading research…

Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.

Dated financials

Price and valuation

Closing price was observed on Sep 21, 2026 (as of snapshot date Sep 22, 2026). Financial reporting periods are shown with each observation.

Closing price

393.16 USD/shares

At Sep 21, 2026

Provider observation · observed Sep 22, 2026

Market capitalization

212.19B USD

At Sep 21, 2026

Provider observation · observed Sep 22, 2026

P/E · trailing 12 months

24.24x

Provider TTM · observed Sep 22, 2026

Free cash flow yield

4.80%

Provider TTM · observed Sep 22, 2026

Compare within the sector

Price to book is particularly useful for financial companies. Price to sales can support comparisons when earnings are negative.

Price to sales

5.57x

Provider TTM · observed Sep 22, 2026

Price to book

18.16x

Provider TTM · observed Sep 22, 2026

Additional valuation measures

Fiscal-year P/E uses the last completed financial year. Earnings yield expresses earnings relative to price as a percentage.

P/E · fiscal year: 27.10x; At Sep 18, 2026
Earnings yield: 4.13%; Provider TTM · observed Sep 22, 2026

Financial statements and ratios

Company disclosures

Revenue · quarter

10.05B USD

At Jun 30, 2026